In 2014 the American College of Cardiology/American Heart Association issued four new guidelines for cardiovascular disease prevention that focused on cardiovascular risk assessment, lifestyle management, obesity management, and blood cholesterol management. The development of an atherosclerotic
cardiovascular disease risk calculator formed the basis of the risk assessment guideline, and the lifestyle management guideline focused on recommending an evidence-based dietary pattern. The blood cholesterol management guideline specifically identified four groups of patients shown to benefit
from moderate-intensity or high-intensity statin therapy from previous clinical trials and abandoned the use of specific low-density lipoprotein (LDL) cholesterol (LDL-C) goal levels on the basis of the lack of clinical trial evidence. The recommendations for treatment with moderate-intensity
or high-intensity statin therapy are based on rigorous evidence from randomized clinical trials. Guidance has since been provided for the use of nonstatin therapies, including cholesterol absorption inhibitor and proprotein convertase subtilisin/kexin type 9 monoclonal antibody therapy when
adequate reduction of LDL-C levels is not achieved with maximally tolerated statin therapy. The recent development and application of these therapies have resulted in remarkable reductions in LDL-C levels that are well tolerated, and preliminary outcome data are promising in showing substantial
atherosclerotic cardiovascular disease event reductions beyond statin therapy.
No References for this article.
No Supplementary Data.
No Article Media
Document Type: Research Article
Publication date: 01 September 2016
More about this publication?
Cardiovascular Innovations and Applications (CVIA) publishes focused articles and original clinical research that explore novel developments in cardiovascular disease, effective control and rehabilitation in cardiovascular disease, and promote cardiovascular innovations and applications for the betterment of public health globally. The journal publishes basic research that has clinical applicability in order to promote timely communication of the latest insights relating to coronary artery disease, heart failure, hypertension, cardiac arrhythmia, prevention of cardiovascular disease with a heavy emphasis on risk factor modification. Cardiovascular Innovations and Applications is the official journal of the Great Wall International Congress of Cardiology (GW-ICC). It aims to continue the work of the GW-ICC by providing a global scientific communication platform for cardiologists that bridges East and West.
- Editorial Board
- Information for Authors
- Submit a Paper
- Subscribe to this Title
- Membership Information
- Information for Advertisers
- Terms & Conditions
- Ingenta Connect is not responsible for the content or availability of external websites